[Lipoproteins HDL and coronary artery disease: a molecular mechanism of fibrate].
The importance of dyslipidemia in the development of cardiovascular disease is now recognized as a central factor of equal, if not greater significance than any other risk factor. Although correction of high level of low-density lipoproteins (LDL) has been regarded now as the main goal of therapy, it has now been reaffirmed that the contribution of low level of high-density lipoproteins (HDL) to the risk of ischaemic heart disease should also be considered. In the therapy of dislipidemias with hipertriglyceridemia and decreased level of HDL lipoprotein fibrates play an especially important role. In the article the molecular mechanism of fibrates action is presented.
Kaletha
Krystian
K
Katedra i Zakład Biochemii Akademii Medycznej w Gdańsku, 80-952 Gdańsk, ul. Debinki 7.
Chodorowski
Zygmunt
Z
Anand
Izabela Sein
IS
Rybakowska
Iwona
I
Nagel-Starczynowska
Gabriela
G
D001629:Bezafibrate / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000097:blood / Q000378:metabolism*; D008078:Cholesterol, LDL / Q000097:blood / Q000378:metabolism*; D022781:Hepatocytes / Q000187:drug effects; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000209:etiology* / Q000235:genetics / Q000378:metabolism*; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects / Q000235:genetics; D014157:Transcription Factors / Q000187:drug effects / Q000235:genetics; D015854:Up-Regulation / Q000187:drug effects / Q000235:genetics
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D001629:Bezafibrate